Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive … – PR Newswire (press release)

Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive
PR Newswire (press release)
Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may

and more »

View full post on asthma – Google News

Asia-Pacific Asthma Therapeutics Market Increased Demand of a Compound Annual Growth Rate (CAGR) of 7.2 … – Medgadget.com (blog)

Asia-Pacific Asthma Therapeutics Market Increased Demand of a Compound Annual Growth Rate (CAGR) of 7.2
Medgadget.com (blog)
Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may

View full post on asthma – Google News

Asthma Therapeutics in Asia-Pacific Markets to 2021 – Launch of Late-Stage Biologics will Drive the Market in Spite … – Business Wire (press release)

Asthma Therapeutics in Asia-Pacific Markets to 2021 – Launch of Late-Stage Biologics will Drive the Market in Spite
Business Wire (press release)
Over the 2015-2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion. Analysis of clinical trials since

and more »

View full post on asthma – Google News

Asthma Therapeutics in Asia-Pacific Markets Key Trends, Size, Growth, Shares And Forecast Research Report 2021 – Medgadget.com (blog)

Asthma Therapeutics in Asia-Pacific Markets Key Trends, Size, Growth, Shares And Forecast Research Report 2021
Medgadget.com (blog)
Researchmoz added Most up-to-date research on “Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns” to its huge collection of research reports.

and more »

View full post on asthma – Google News

Asthma Therapeutics In Asia-Pacific Market Research To Reach Over $5.6 billion 2021 – High Prevalence And Launch … – Medgadget.com (blog)

Asthma Therapeutics In Asia-Pacific Market Research To Reach Over $5.6 billion 2021 – High Prevalence And Launch
Medgadget.com (blog)
MrrBiz45 The report analyzes and presents an overview on “Asthma Therapeutics In Asia-Pacific Markets To 2021 – High Prevalence And Launch Of Late-Stage Biologics Will Drive The Market In Spite Of Affordability Concerns” worldwide. Asthma is a …

View full post on asthma – Google News

Respiratory disease in the Asia-Pacific region: Cough as a key symptom.

Related Articles

Respiratory disease in the Asia-Pacific region: Cough as a key symptom.

Allergy Asthma Proc. 2016 Jan 21;

Authors: Cho SH, Ghoshal AG, Lin HC, Muttalif AR, Thanaviratananich S, Bagga S, Faruqi R, Sajjan S, Brnabic AJ, Dehle FC, Wang DY

Abstract
BACKGROUND: Respiratory diseases represent a significant impact on health care. A cross-sectional, multicountry (India, Korea, Malaysia, Singapore, Taiwan, and Thailand) observational study was conducted to investigate the proportion of adult patients who received care for a primary diagnosis of asthma, allergic rhinitis (AR), chronic obstructive pulmonary disease (COPD), or rhinosinusitis.
OBJECTIVE: To determine the proportion of patients who received care for asthma, AR, COPD, and rhinosinusitis, and the frequency and main symptoms reported.
METHODS: Patients ages greater than or equal to 18 years, who presented to a physician with symptoms that met the diagnostic criteria for a primary diagnosis of asthma, AR, COPD, or rhinosinusitis were enrolled. Patients and physicians completed a survey that contained questions related to demographics and respiratory symptoms.
RESULTS: A total of 13,902 patients with a respiratory disorder were screened, of whom 7030 were eligible and 5250 enrolled. The highest percentage of patients who received care had a primary diagnosis of AR (14.0% [95% confidence interval {CI}, 13.4 -14.6%]), followed by asthma (13.5% [95% CI, 12.9 -14.1%]), rhinosinusitis (5.4% [95% CI, 4.6 -5.3%]), and COPD (4.9% [95% CI, 5.0 -5.7%]). Patients with a primary diagnosis of COPD (73%), followed by asthma (61%), rhinosinusitis (59%), and AR (47%) most frequently reported cough as a symptom. Cough was the main reason for seeking medical care among patients with a primary diagnosis of COPD (43%), asthma (33%), rhinosinusitis (13%), and AR (11%).
CONCLUSION: Asthma, AR, COPD, and rhinosinusitis represent a significant proportion of respiratory disorders in patients who presented to health care professionals in the Asia-Pacific region, many with concomitant disease. Cough was a prominent symptom and the major reason for patients with respiratory diseases to seek medical care.

PMID: 26802834 [PubMed – as supplied by publisher]

View full post on pubmed: asthma